Redmile Group, a healthcare investment organization, led a $125m round in Saluda Medical, a medical device company, with participation from Fidelity Management & Research Company and T. Rowe Price Associates. "We are thrilled to partner with this group of leading healthcare investors who share our vision of elevating the standard of care in neuromodulation fields with large unmet patient needs. The full impact of our innovation can only be realized by enabling more patients to be treated with our evidence-based technologies designed to improve long-term outcomes while reducing the burden of care, and we wish to thank our new and existing investors for their partnership in our journey to achieve this mission," Jim Schuermann, aluda Medical President and CEO.